| Autor: |
Zhuravleva MV; I.M. Sechenov First Moscow State Medical University (Sechenov University)., Prokofiev AB; I.M. Sechenov First Moscow State Medical University (Sechenov University)., Shih EV; I.M. Sechenov First Moscow State Medical University (Sechenov University)., Serebrova SY; I.M. Sechenov First Moscow State Medical University (Sechenov University)., Gorodetskaya GI; I.M. Sechenov First Moscow State Medical University (Sechenov University). |
| Jazyk: |
ruština |
| Zdroj: |
Kardiologiia [Kardiologiia] 2018 Oct (10), pp. 88-95. |
| Abstrakt: |
In this article we have described clinical pharmacology and data of clinical studies of an innovational drug valsartan + sacubitril in patients with chronic heart failure (CHF). The use of supramolecular complex valsartan + sacubitril allows to elevate quality of life and improve prognosis of patients with CHF. High efficacy of valsartan+sacubitril relative to impact on composite primary end-point (cardiovascular death + hospitalization due to CHF) was demonstrated in the clinical trial PARADIGM-HF in which it was compared with angiotensin converting enzyme inhibitor enalapril. Advantages of the use of valsartan + sacubitril for the budget were demonstrated in pharmacoeconomic studies. These advantages are maximally realized at long-term administration. Cost-efficacy of the use of valsartan+sacubitril in pharmacotherapy of CHF is comparable with that of statins in the treatment of ischemic heart disease or implantation of a cardioverter-defibrillator in prevention of sudden cardiac death. Thus, introduction of the drug into practice can be expected to reduce budget expenditures. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
